Home›Earnings›Analyst Ratings›Red Cat, Taysha and Solaris highlighted for potential…

Red Cat, Taysha and Solaris highlighted for potential 100% upside

For Red Cat Holdings, analysts cited Q2 2026 results including a 26-cent loss per share and Army revenue of about 50% of sales in the first half of 2026.

Reported · Written up by our desk · Analyst Ratings

MarketBeat Ratings points to three higher-risk, higher-upside stocks it says could roughly double in value, including Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources.

For Red Cat, the outlet notes the company has faced stability issues tied to a history of quarterly losses, including a Q2 2026 quarterly loss per share of 26 cents, 5 cents wider than analysts expected.

The report also highlights that Red Cat’s business leans on government work, with Army revenue accounting for about 50% of sales in the first half of 2026, while the company posted revenue growth of 520% year over year in Q2 2026.

MarketBeat Ratings adds that analysts estimate Red Cat shares could rise 115% to $18 per share, and it flags further optimism around Taysha Gene Therapies following an eventful second quarter, including progress on drug development and manufacturing capacity.

The provided material ends as it begins describing Taysha’s manufacturing capacity update tied to a partnership with Catal, without additional figures or conclusions for the other named stock.

More like this

Sources